CLINICAL TRIALS PROFILE FOR KYZATREX
✉ Email this page to a colleague
All Clinical Trials for KYZATREX
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT06082817 ↗ | An Open-Label Study of 50 mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women With Low Testosterone and HSDD | Not yet recruiting | San Diego Sexual Medicine | Phase 2 | 2023-12-01 | This is an unblinded study to be conducted at a single research center, San Diego Sexual Medicine. Eligible subjects will receive 50 mg capsules of Kyzatrax® to be taken orally daily over a 3-month period. Multiple blood samples will be taken at baseline and on days 7, 28 and 56 to assess safety and pharmacokinetics of the testosterone. After the informed consent is signed and for up to 84 days after baseline, subjects will have serial blood samples collected in addition to other routine study procedures (e.g. vital signs measured, adverse events assessed, validated outcome scales completed). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for KYZATREX
Condition Name
Clinical Trial Locations for KYZATREX
Trials by Country
Clinical Trial Progress for KYZATREX
Clinical Trial Phase
Clinical Trial Sponsors for KYZATREX
Sponsor Name
